Single User License
INR 168550
Site License
INR 337100
Corporate User License
INR 505650

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Methicillin-Resistant Staphylococcus Aureus MRSA Infections Global Clinical Trials Review, H1

Methicillin-Resistant Staphylococcus Aureus MRSA Infections Global Clinical Trials Review, H1


  Request for Sample Report

Executive Summary

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Global Clinical Trials Review, H1, 2015

GlobalData's clinical trial report, "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Global Clinical Trials Review, H1, 2015" provides an overview of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Introduction 7

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 7

Report Guidance 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Five Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials 16

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials 19

Clinical Trials by Phase in E7 Countries 20

Clinical Trials in E7 Countries by Trial Status 21

Clinical Trials by Phase 22

In Progress Trials by Phase 23

Clinical Trials by Trial Status 24

Clinical Trials by End Point Status 25

Unaccomplished Trials of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 26

Subjects Recruited Over a Period of Time 29

Clinical Trials by Sponsor Type 30

Prominent Sponsors 31

Top Companies Participating in Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials 32

Prominent Drugs 33

Latest Clinical Trials News on Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 34

Jun 02, 2015: Discovery of breakthrough MRSA compound 34

May 21, 2015: ContraFect Announces First Healthy Volunteer Dosed With CF-301 34

Apr 29, 2015: ContraFect Announces Commencement of Phase 1 Clinical Trial of CF-301 for Staph Bloodstream Infections, Including MRSA 35

Apr 27, 2015: TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance 35

Apr 24, 2015: New Data Shows Greater In Vitro Potency for VIBATIV (Telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, Compared to Alternative Antibiotic Treatments 36

Apr 16, 2015: Theravance Biopharma to Present New Data Highlighting in vitro Potency of VIBATIV (telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, at 2015 ECCMID Conference 37

Clinical Trial Profiles 39

Clinical Trial Overview of Top Companies 39

Pfizer Inc. 39

Clinical Trial Overview of Pfizer Inc. 39

Khorakiwala Holdings and Investments Private Limited 40

Clinical Trial Overview of Khorakiwala Holdings and Investments Private Limited 40

AstraZeneca Plc 41

Clinical Trial Overview of AstraZeneca Plc 41

GlaxoSmithKline Plc 42

Clinical Trial Overview of GlaxoSmithKline Plc 42

Forest Laboratories, Inc. (Inactive) 43

Clinical Trial Overview of Forest Laboratories, Inc. (Inactive) 43

Cubist Pharmaceuticals, Inc. (Inactive) 44

Clinical Trial Overview of Cubist Pharmaceuticals, Inc. (Inactive) 44

Nabriva Therapeutics AG 45

Clinical Trial Overview of Nabriva Therapeutics AG 45

MicuRx Pharmaceuticals, Inc. 46

Clinical Trial Overview of MicuRx Pharmaceuticals, Inc. 46

Jaguar Holding Company II 47

Clinical Trial Overview of Jaguar Holding Company II 47

Enanta Pharmaceuticals, Inc. 48

Clinical Trial Overview of Enanta Pharmaceuticals, Inc. 48

Clinical Trial Overview of Top Institutes / Government 49

University of California, Irvine 49

Clinical Trial Overview of University of California, Irvine 49

Washington University School of Medicine 50

Clinical Trial Overview of Washington University School of Medicine 50

Ann & Robert H. Lurie Children's Hospital of Chicago 51

Clinical Trial Overview of Ann & Robert H. Lurie Children's Hospital of Chicago 51

Assistance Publique-Hopitaux de Paris 52

Clinical Trial Overview of Assistance Publique-Hopitaux de Paris 52

Menzies School of Health Research 53

Clinical Trial Overview of Menzies School of Health Research 53

Seoul National University Bundang Hospital 54

Clinical Trial Overview of Seoul National University Bundang Hospital 54

Uniformed Services University of the Health Sciences 55

Clinical Trial Overview of Uniformed Services University of the Health Sciences 55

University Hospital, Geneva 56

Clinical Trial Overview of University Hospital, Geneva 56

University Medicine Greifswald 57

Clinical Trial Overview of University Medicine Greifswald 57

Wilford Hall Medical Center 58

Clinical Trial Overview of Wilford Hall Medical Center 58

Five Key Clinical Profiles 59

Appendix 89

Abbreviations 89

Definitions 89

Research Methodology 90

Secondary Research 90

About GlobalData 91

Contact Us 91

Disclaimer 91

Source 92

List of Figures

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region (%), 2015* 8

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 11

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 12

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 13

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 14

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015* 15

Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2015* 16

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18

Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2015* 19

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase (%), 2015* 22

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 23

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 29

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 30

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 31

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33

GlobalData Methodology 90

List of Tables

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region, 2015* 8

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 11

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 12

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries, 2015* 13

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 14

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015* 15

Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2015* 16

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18

Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2015* 19

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase, 2015* 22

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 23

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Suspended Clinical Trials, 2015* 26

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Withdrawn Clinical Trials, 2015* 27

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Terminated Clinical Trials, 2015* 28

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 29

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 30

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 31

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 39

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Khorakiwala Holdings and Investments Private Limited, 2015* 40

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca Plc, 2015* 41

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline Plc, 2015* 42

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Forest Laboratories, Inc. (Inactive), 2015* 43

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Cubist Pharmaceuticals, Inc. (Inactive), 2015* 44

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Nabriva Therapeutics AG, 2015* 45

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by MicuRx Pharmaceuticals, Inc., 2015* 46

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Jaguar Holding Company II, 2015* 47

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Enanta Pharmaceuticals, Inc., 2015* 48

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Irvine, 2015* 49

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2015* 50

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Ann & Robert H. Lurie Children's Hospital of Chicago, 2015* 51

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique-Hopitaux de Paris, 2015* 52

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Menzies School of Health Research, 2015* 53

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Bundang Hospital, 2015* 54

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Uniformed Services University of the Health Sciences, 2015* 55

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital, Geneva, 2015* 56

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University Medicine Greifswald, 2015* 57

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Wilford Hall Medical Center, 2015* 58

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Pfizer Inc.

Khorakiwala Holdings and Investments Private Limited

AstraZeneca Plc

GlaxoSmithKline Plc

Nabriva Therapeutics AG

MicuRx Pharmaceuticals, Inc.

Jaguar Holding Company II

Enanta Pharmaceuticals, Inc

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com